New Prostate Cancer Test From Genomic Health Reveals Positive Results in Recent Clinical Validation Study

New Prostate Cancer Test From Genomic Health Reveals Positive Results in Recent Clinical Validation Study
Genomic Health, Inc., will present results from nine different studies of Oncotype DX®, a genomic-based diagnostic test, in prostate, breast, and renal cancers at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid. Included in the program is the first presentation of relevant positive results from an additional large independent clinical validation study of Oncotype

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *